Conformationally constrained analogues of N-(piperidinyl)-5-(4- chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): Design, synthesis, computational analysis, and biological evaluations

Journal of Medicinal Chemistry

Volumn 51, Issue 12, 2008, Pages 3526-3539

  Zhang, Yanan ^a   Burgess, Jason P ^a   Brackeen, Marcus ^a   Gilliam, Anne ^a   Mascarella, S Wayne ^a   Page, Kevin ^a   Seltzman, Herbert H ^a   Thomas, Brian F ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 9 CHLORO 1 (2,4 DICHLOROPHENYL) N PIPERIDIN 1 YL 4,5,6,7 TETRAHYDRO 1H BENZO[7,8]CYCLOOCTA[1,2 C]PYRAZOLE 3 CARBOXAMIDE; RIMONABANT;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENERGY; HUMAN; HUMAN CELL; MOLECULAR RECOGNITION; NONHUMAN; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; CRICETINAE; CRICETULUS; DRUG DESIGN; ELECTROSTATICS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PIPERIDINES; PYRAZOLES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 45749133911     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8000778     Document Type: Article

References (49)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346 (6284), 561-564.
2. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365 (6441), 61-65.
3. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258 (5090), 1946-1949.
4. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Almog, S.; Martin, B. R.; Compton, D. R.; et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 1995, 50 (1), 83-90.
5. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 1995, 215 (1), 89-97.
6. Breivogel, C. S.; Walker, J. M.; Huang, S. M.; Roy, M. B.; Childers, S. R. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology 2004, 47 (1), 81-91.
7. Carrier, E. J.; Patel, S.; Hillard, C. J. Endocannabinoids in neuroimmunology and stress. Curr. Drug Targets CNS Neurol. Disord. 2005, 4 (6), 657-665.
8. Di Marzo, V.; Petrocellis, L. D. Plant, synthetic, and endogenous cannabinoids in medicine. Annu. Rev. Med. 2006, 57, 553-574.
9. Karanian, D. A.; Bahr, B. A. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states. Curr. MoI. Med. 2006, 6 (6), 677-684.
10. Pertwee, R. G. Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 2005, (168), 1-51.
11. Felder, C. C.; Dickason-Chesterfield, A. K.; Moore, S. A. Cannabinoids biology: the search for new therapeutic targets. Mol. Interventions 2006, 6 (3), 149-161.
12. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350 (2-3), 240-244.
13. Barth, F. CB1 cannabinoid receptor antagonists. Annu. Rep. Med. Chem. 2005, Vol 40 (40), 103-118.
14. Lange, J. H.; Kruse, C. G. Recent advances in CB1 cannabinoid receptor antagonists. Curr. Opin. Drug Discovery Dev. 2004, 7 (4), 498-506.
15. Lange, J. H.; Kruse, C. G. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discovery Today 2005, 10 (10), 693-702.
16. Muccioli, G. G.; Lambert, D. M. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem. 2005, 12 (12), 1361-1394.
17. Francisco, M. E. Y.; Seltzman, H. H.; Gilliam, A. F.; Mitchell, R. A.; Rider, S. L.; Pertwee, R. G.; Stevenson, L. A.; Thomas, B. F. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-l- (2,4-dichlorophenyl)-4-methyl-l/7-pyrazole-3-car-boxamide (SR141716). J. Med. Chem. 2002, 45 (13), 2708-2719.
18. Gouldson, P.; Calandra, B.; Legoux, P.; Kerneis, A.; Rinaldi-Carmona, M.; Barth, F.; Le Fur, G.; Ferrara, P.; Shire, D. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur. J. Pharmacol. 2000, 401 (1), 17-25.
19. Hurst, D.; Umejiego, U.; Lynch, D.; Seltzman, H.; Hyatt, S.; Roche, M.; McAllister, S.; Fleischer, D.; Kapur, A.; Abood, M.; Shi, S.; Jones, J.; Lewis, D.; Reggio, P. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J. Med. Chem. 2006, 49 (20), 5969-5987.
20. Hurst, D. P.; Lynch, D. L.; Barnett-Norris, J.; Hyatt, S. M.; Seltzman, H. H.; Zhong, M.; Song, Z. H.; Nie, J.; Lewis, D.; Reggio, P. H. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 2002, 62 (6), 1274-1287.
21. McAllister, S. D.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D.; Reggio, P. H.; Abood, M. E. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem. 2004, 279 (46), 48024-48037.
22. McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett-Norris, J.; Lynch, D. L.; Reggio, P. H.; Abood, M. E. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem. 2003, 46 (24), 5139-5152.
23. Hurst, D. P.; Lynch, D. L.; Barnett-Norris, J.; Hyatt, S. M.; Seltzman, H. H.; Zhong, M.; Song, Z. H.; Nie, J.; Lewis, D.; Reggio, P. H. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 2002, 62 (6), 1274-1287.
24. Hurst, D.; Umejiego, U.; Lynch, D.; Seltzman, H.; Hyatt, S.; Roche, M.; McAllister, S.; Fleischer, D.; Kapur, A.; Abood, M.; Shi, S.; Jones, J.; Lewis, D.; Reggio, P. Biarylpyrazole Inverse Agonists at the Cannabinoid CB1 Receptor: Importance of the C-3 Carboxamide Oxygen/Lysine3.28(192) Interaction. J. Med. Chem. 2006, 49 (20), 5969-5987.
25. Katoch-Rouse, R.; Pavlova, O. A.; Caulder, T.; Hoffman, A. F.; Mukhin, A. G.; Horti, A. G. Synthesis, Structure-Activity Relationship, and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity. J. Med. Chem. 2003, 46 (4), 642-645.
26. Thomas, B. F.; Zhang, Y.; Brackeen, M.; Page, K. M.; Mascarella, S. W.; Seltzman, H. H. Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs. AAPS J. 2006, 8 (4), E665-671.
27. Francisco, M. E. Y.; Burgess, J. P.; George, C.; Bailey, G. S.; Gilliam, A. F.; Seltzman, H. H.; Thomas, B. F. Structure elucidation of a novel ring-constrained biaryl pyrazole CB, cannabinoid receptor antagonist. Magn. Reson. Chem. 2003, 41 (4), 265-268.
28. Murineddu, G.; Ruiu, S.; Loriga, G.; Manca, I.; Lazzari, P.; Reali, R.; Pani, L.; Toma, L.; Pinna, G. A. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichlorophenyl)-N-piperidin-1-yl-1,4,5, 6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. J. Med. Chem. 2005, 48 (23), 7351-7362.
29. Murineddu, G.; Ruiu, S.; Mussinu, J. M.; Loriga, G.; Grella, G. E.; Carai, M. A.; Lazzari, P.; Pani, L.; Pinna, G. A. Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[ g]indazole-based ligands for cannabinoid receptors. Bioorg. Med. Chem. 2005, 13 (9), 3309-3320.
30. Mussinu, J. M.; Ruiu, S.; Mule, A. C.; Pau, A.; Carai, M. A.; Loriga, G.; Murineddu, G.; Pinna, G. A. Tricyclic Pyrazoles. Part 1: Synthesis and Biological Evaluation of Novel 1,4-Dihydroindeno[1,2-c]pyrazol-based Ligands for CB(1)and CB(2)Cannabinoid Receptors. Bioorg. Med. Chem. 2003, 11 (2), 251-263.
31. Stoit, A. R.; Lange, J. H.; Hartog, A. P.; Ronken, E.; Tipker, K.; Stuivenberg, H. H.; Dijksman, J. A.; Wals, H. C.; Kruse, C. G. Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem. Pharm. Bull. (Tokyo) 2002, 50 (8), 1109-1113.
32. Seltzman, H. H.; Carroll, F. I.; Burgess, J. P.; Wyrick, C. D.; Burch, D. F. Tritiation of SR141716 by metallation-iodination-reduction: tritium-proton nOe study. J. Labelled Compd. Radiopharm. 2002, 45 (1), 59-70.
33. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 1999, 42 (4), 769-776.
34. Hu, Y. M.; Ishikawa, Y.; Hirai, K.; Tomioka, H. Spectroscopic and product studies of the effect of para substituents on the reactivity of triplet bis(2,6-dimethylphenyl)carbenes. Bull. Chem. Soc. Jpn. 2001, 74 (11), 2207-2218.
35. Jaime, C.; Font, J. Conformational-Analysis of Bridged Biphenyls and 2,2′-Bipyridines - Empirical Force-Field Calculations (Mm2-V4). J. Org. Chem. 1990, 55 (9), 2637-2644.
36. Thummel, R. P.; Lefoulon, F.; Cantu, D.; Mahadevan, R. Polyaza Cavity-Shaped Molecules - Annelated Derivatives of 2-(2′-Pyridyl)-1,8- naphthyridine and 2,2′-bi-1,8-Naphthyridine. J. Org. Chem. 1984, 49 (12), 2208-2212.
37. Thummel, R. P.; Lefoulon, F. Polyaza Cavity Shaped Molecules. 2. Annelated Derivatives of 2,2′-Biquinoline and the Corresponding N-Oxides. J. Org. Chem. 1985, 50 (5), 666-670.
38. Thummel, R. P.; Lefoulon, F.; Mahadevan, R. Polyaza Cavity Shaped Molecules. 5. Annelated Derivatives of 2,2′-Bipyridine. J. Org. Chem. 1985, 50 (20), 3824-3828.
39. Thummel, R. P.; Hegde, V. Polyaza-Cavity Shaped Molecules. 14. Annelated 2-(2′-Pyridyl)indoles, 2,2′-Biindoles, and Related Systems. J. Org. Chem. 1989, 54 (7), 1720-1725.
40. Thummel, R. P.; Goulle, V.; Chen, B. Bridged Derivatives of 2,2′-Biimidazole. J. Org. Chem. 1989, 54 (13), 3057-3061.
41. Dambacher, J.; Anness, R.; Pollock, P.; Bergdahl, M. Highly diastereoselective conjugate additions of monoorganocopper reagents to chiral imides. Tetrahedron 2004, 60 (9), 2097-2110.
42. Huck, B. R.; Fisk, J. D.; Guzei, I. A.; Carlson, H. A.; Gellman, S. H. Secondary structural preferences of 2,2-disubstituted pyrrolidine-4-carboxylic acid oligomers: beta-peptide foldamers that cannot form internal hydrogen bonds. J. Am. Chem. Soc. 2003, 125 (30), 9035-9037.
43. Langenhan, J. M.; Guzei, I. A.; Gellman, S. H. Parallel sheet secondary structure in beta-peptides. Angew. Chem., Int. Ed. 2003, 42 (21), 2402-2405.
44. Oki, M., Application of Dynamic NMR Spectroscopy to Organic Chemistry; Wiley-VCH: Weinheim, 1985.
45. Tucci, F. C.; Hu, T.; Mesleh, M. F.; Bokser, A.; Allsopp, E.; Gross, T. D.; Gu, Z. Q.; Zhu, Y. F.; Struthers, R. S.; Ling, N.; Chen, C. Atropisomeric property of 1-(2,6-difluorobenzyl)-3-[(2R)-amino-2-phenethyl]-5-(2- fluoro-3-methoxyphenyl)-6-methyluracil. Chirality 2005, 17 (9), 559-564.
46. Huelgas, G.; Bernes, S.; Sanchez, M.; Quintero, L.; Juaristi, E.; de Parrodi, C. A.; Walsh, P. J. Synthesis and dynamics of atropisomeric (S)-N-(alpha-phenylethyl)benzamides. Tetrahedron 2007, 63 (51), 12655-12664.
47. Ahmed, A.; Bragg, R. A.; Clayden, J.; Lai, L. W.; McCarthy, C.; Pink, J. H.; Westlund, N.; Yasin, S. A. Barriers to rotation about the chiral axis of tertiary aromatic amides. Tetrahedron 1998, 54 (43), 13277-13294.
48. Johnson, M. R.; Melvin, L. S., The Discovery of Nonclassical Cannabinoid Analgetics. CRC Press Inc.: Boca Raton, FL, 1986; pp 121-145..
49. Ruiu, S.; Pinna, G. A.; Marchese, G.; Mussinu, J. M.; Saba, P.; Tambaro, S.; Casti, P.; Vargiu, R.; Pani, L. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther. 2003, 306 (1), 363-370.